Rosetta Inpharmatics Posts Greater-than-expected Q3 Losses | GenomeWeb

NEW YORK, Oct 26 - Rosetta Inpharmatics reported greater-than-expected third quarter 2000 losses Thursday, falling 12 cents per share short of Wall Street’s predictions.

For the third quarter of 2000, the company reported a net loss of $8.4 million, or 40 cents per diluted share, compared to a net loss of $5.0 million, or $1.11 per share for the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.